A phase 1 study of Olaparib, a poly ADP-ribose polymerase-1 (PARP) inhibitor, in combination with metronomic cyclophosphamide in patients with metastatic BRCA-associated cancer, triple negative breast cancer or serous ovarian cancer (ANZ 1103 SOLACE)
收藏DataCite Commons2023-06-08 更新2024-07-13 收录
下载链接：
https://doi.breastcancertrials.org.au/78
下载链接
链接失效反馈官方服务：
资源简介：
HeSANDA 1.0.0
提供机构：
Breast Cancer Trials (BCT)
创建时间：
2023-05-31
